homocysteine hydrochloride | 20244-20-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: homocysteine hydrochloride
• 英文别名: Homocysteine hydrochloride；(2S)-2-amino-4-sulfanylbutanoic acid;hydrochloride
• CAS: 20244-20-6
• 化学式: C₄H₉NO₂S*ClH
• 分子量: 171.648
• InChiKey: PDUMWBLAPMSFGD-DFWYDOINSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.14
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  64.3
• 氢给体数：
  4
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-溴丙烯 、 homocysteine hydrochloride 在 氨 作用下， 以 乙醇 、 水 为溶剂， 反应 20.0h， 生成 S-allyl-L-homocysteine
  参考文献：
  名称：

  Influence of α-methylation in constructing stapled peptides with olefin metathesis

  摘要：

  Ring-closing metathesis is commonly utilized in peptide macro-cyclization. The influence of alpha-methylation of the amino acids bearing the olefin moieties has never been systematically studied. In this report, controlled reactions unambiguously indicate that alpha-methylation at the N-terminus of the metathesis sites is crucial for this reaction to occur. Also, we first elucidated that the E-isomers of stapled peptides are significantly more helical than the Z-isomers. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2014.08.004

文献信息

• Synthesis and Antibacterial Activity of 1β-Methyl-2-(5-substituted thiazolidinopyrrolidin-3-ylthio)carbapenems and Related Compounds
  作者：Chang-Hyun Oh、Han-Won Cho、In-Kyu Lee、Jai-Yang Gong、Joung-Hoon Choi、Jung-Hyuck Cho

  DOI：10.1002/1521-4184(200204)335:4<152::aid-ardp152>3.0.co;2-b

  日期：2002.4

  The synthesis of a new series of 1β‐methylcarbapenems containing the substituted thiazolidinopyrrolidine moiety is described. Their in vitro antibacterial activities against both Gram‐positive and Gram‐negative bacteria were tested and the effect of substituent on the thiazolidine ring was investigated.A particular compound (18 c) having a 2‐amide substituted thiazolidine moiety showed the most potent

  描述了含有取代的噻唑烷并吡咯烷部分的新系列 1β-甲基碳青霉烯类的合成。测试了它们对革兰氏阳性菌和革兰氏阴性菌的体外抗菌活性，并研究了取代基对噻唑烷环的影响。具有 2-酰胺取代的噻唑烷部分的特定化合物 (18 c) 显示出最有效的抗菌活性.
• [EN] TETRAAZABICYCLO-MACROCYCLE BASED MANGANESE CHELATE COMPOUNDS SUITABLE AS MRI IMAGING AGENTS<br/>[FR] COMPOSÉS DE CHÉLATE DE MANGANÈSE À BASE DE TÉTRAAZABICYCLO-MACROCYCLE APPROPRIÉS EN TANT QU'AGENTS D'IMAGERIE IRM
  申请人：GE HEALTHCARE AS

  公开号：WO2018115314A1

  公开（公告）日：2018-06-28

  The invention provides compounds of formula (I) representing a polyaza-macrocycle with carboxylic acid side arms complexing Manganese as core metal. The complexes are suitable for use as contrast agents in magnetic resonance imaging (MRI).

  该发明提供了公式(I)的化合物，代表具有羧酸侧臂的聚氮杂大环，与锰作为核心金属形成络合物。这些络合物适用于作为磁共振成像（MRI）中的对比剂。
• New pH-responsive gemini lipid derived co-liposomes for efficacious doxorubicin delivery to drug resistant cancer cells
  作者：Parikshit Moitra、Krishan Kumar、Sourav Sarkar、Paturu Kondaiah、Wei Duan、Santanu Bhattacharya

  DOI：10.1039/c7cc03320f

  日期：——

  A new pH-sensitive co-liposomal formulation was developed which could efficiently transport doxorubicin across the DOX-resistant cancer cells.

  开发了一种新的pH敏感的共混脂质体配方，可以有效地将阿霉素跨越DOX耐药癌细胞传输。
• .alpha.-Halomethyl derivatives of .alpha.-amino acids
  申请人：Merrell Toraude et Compagnie

  公开号：US04438270A1

  公开（公告）日：1984-03-20

  Novel halomethyl derivatives of .alpha.-amino acids of the following general structure: wherein Y is ClCH.sub.2, F.sub.2 CH--, F.sub.3 C--, ClCH.sub.2 --, Cl.sub.2 CH--; Z is .beta.-methylthioethyl, .beta.-thioethyl, .beta.-benzylthioethyl; S-(5'-desoxyadenosin-5'-yl)-S-methylthioethyl, .gamma.-guanidinopropyl, R.sub.a HN(CH.sub.2).sub.n -- wherein n is the integer 3 or 4 or ##STR1## wherein Y.sub.2 is F.sub.2 CH--, or F.sub.3 C--; each of R.sub.a and R.sub.b can be the same or different and is hydrogen, alkylcarbonyl wherein the alkyl moiety has from 1 to 4 carbon atoms and is straight or branched, alkoxycarbonyl wherein the alkoxy moiety has from 1 to 4 carbon atoms and is straight or branched, or ##STR2## wherein R.sub.2 is hydrogen, a straight or branched lower alkyl group of from 1 to 4 carbon atoms, benzyl or .rho.-hydroxybenzyl; R.sub.1 is hydroxy, a straight or branched alkoxy group of from 1 to 8 carbon atoms, --NR.sub.4 R.sub.5 wherein each of R.sub.4 and R.sub.5 is hydrogen or a lower alkyl group of from 1 to 4 carbon atoms, or ##STR3## wherein R.sub.3 is hydrogen, a straight or branched lower alkyl group of from 1 to 4 carbon atoms, benzyl or .rho.-hydroxybenzyl; and the lactams thereof when Z is R.sub.a HN(CH.sub.2).sub.n -- and each of R.sub.a and R.sub.b is hydrogen; with the provisos that when Z is .gamma.-guanidinopropyl or .beta.-methylthioethyl, Y is FCH.sub.2 --, F.sub.2 CH-- or F.sub.3 C--; when Z is .gamma.-guanidinopropyl, R.sub.1 is hydroxy; and when Z is .beta.-thioethyl, .beta.-benzylthioethyl, S-(5'-desoxyadenosin-5'-yl)-S-methylthioethyl ##STR4## Y and Y.sub.2 are FCH.sub.2 --, F.sub.2 CH--, or F.sub.3 C-- and are the same, each of R.sub.a and R.sub.b is hydrogen and R.sub.1 is hydroxy; and pharmaceutically acceptable salts and individual optical isomers thereof.

  以下是具有以下一般结构的.alpha.-氨基酸的新型卤甲基衍生物：其中Y是ClCH.sub.2，F.sub.2 CH--，F.sub.3 C--，ClCH.sub.2 --，Cl.sub.2 CH--; Z是.beta.-甲基硫乙基，.beta.-硫乙基，.beta.-苄基硫乙基; S-(5'-去氧腺苷-5'-基)-S-甲基硫乙基，.gamma.-鸟氨酸基丙基，R.sub.a HN(CH.sub.2).sub.n --其中n是整数3或4或##STR1##其中Y.sub.2是F.sub.2 CH--或F.sub.3 C--;R.sub.a和R.sub.b中的每一个可以相同也可以不同，并且是氢，烷基羰基，其中烷基部分具有1到4个碳原子并且是直链或支链，烷氧基羰基，其中烷氧基部分具有1到4个碳原子并且是直链或支链，或##STR2##其中R.sub.2是氢，1到4个碳原子的直链或支链低烷基，苄基或.rho.-羟基苄基; R.sub.1是羟基，1到8个碳原子的直链或支链烷氧基，--NR.sub.4 R.sub.5其中R.sub.4和R.sub.5中的每一个是氢或1到4个碳原子的低烷基，或##STR3##其中R.sub.3是氢，1到4个碳原子的直链或支链低烷基，苄基或.rho.-羟基苄基;以及当Z为R.sub.a HN(CH.sub.2).sub.n --且R.sub.a和R.sub.b中的每一个都是氢时的内酰胺;条件是当Z为.gamma.-鸟氨酸基丙基或.beta.-甲基硫乙基时，Y为FCH.sub.2 --，F.sub.2 CH--或F.sub.3 C--;当Z为.gamma.-鸟氨酸基丙基时，R.sub.1为羟基;当Z为.beta.-硫乙基，.beta.-苄基硫乙基，S-(5'-去氧腺苷-5'-基)-S-甲基硫乙基##STR4##时，Y和Y.sub.2均为FCH.sub.2 --，F.sub.2 CH--或F.sub.3 C--并且相同，R.sub.a和R.sub.b中的每一个均为氢且R.sub.1为羟基;以及其药学上可接受的盐和个别光学异构体。
• Method of inhibiting protein tyrosine phosphatase 1B and/or T-cell protein tyrosine phosphatase 4 and/or other PTPases with an Asp residue at position 48
  申请人：Novo Nordisk A/S

  公开号：US07115624B1

  公开（公告）日：2006-10-03

  The present invention provides a method of inhibiting a member of a family of Protein Tyrosine Phosphatases (PTPases, PTPs) such as PTP1B, TC-PTP, CD45, SHP-1, SHP-2, PTPα, PTPε, PTPμ, PTPδ, PTPσ, PTPζ, PTPβ, PTPD1, PTPD2, PTPH1, PTP-MEG1, PTP-LAR, and HePTP by exposing said Ptpase member by administration to a host or otherwise to at least one compound with certain structural, physical and spatial characteristics that allow for the interaction of said compound with specific residues of the active site of PTP1B and/or TC-PTP. These compounds are indicated in the management or treatment of a broad range of diseases such as autoimmune diseases, acute and chronic inflammation, osteoporosis, various forms of cancer and malignant diseases, and type I diabetes and type II diabetes, as well as in the isolation of PTPases and in elucidation or further elucidation of their biological function.

  本发明提供了一种抑制蛋白酪氨酸磷酸酶（PTPases，PTPs）家族成员（如PTP1B、TC-PTP、CD45、SHP-1、SHP-2、PTPα、PTPε、PTPμ、PTPδ、PTPσ、PTPζ、PTPβ、PTPD1、PTPD2、PTPH1、PTP-MEG1、PTP-LAR和HePTP）的方法，通过将至少一种具有特定结构、物理和空间特征的化合物与PTP1B和/或TC-PTP的活性位点上的特定残基相互作用，使该PTPase成员暴露于宿主或以其他方式进行管理或治疗。这些化合物适用于管理或治疗广泛的疾病，如自身免疫性疾病、急性和慢性炎症、骨质疏松症、各种癌症和恶性疾病、1型糖尿病和2型糖尿病，以及在PTPases的分离和阐明或进一步阐明其生物学功能方面。